EUVIMEDEUVIMED entdecken
Klinische Studie (Phase IV)VergleichsstudieRandomisierte kontrollierte Studie

Clinical Trial: Rifaximin Versus Low FODMAP Diet in Irritable Bowel Syndrome

Kee Huat Chuah iD, Qing Yuan Loo, Audrey Joe Chii Loh, Jing Yi Leong, Wah Loong Chan, Xin Hui Khoo, Kim Leng Wong, Sarala Panirsheeluam, Vicraman Natarajan, Ai Kah Ng, Hazreen Abdul Majid, Sanjiv Mahadeva iD

Alimentary Pharmacology & Therapeutics · 2026

DOI: 10.1111/apt.70420 ↗

Kurz gefasst

Klinische Studie (Phase IV) in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2026. Verfasst von Kee Huat Chuah und 11 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology and Hepatology Unit, Department of Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia. Hauptthemen laut MEDLINE: Diet, Carbohydrate-Restricted, Gastrointestinal Agents, Irritable Bowel Syndrome, Rifamycins. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: UMSC C.A.R.E Research Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Rifaximin and the low FODMAP diet (LFD) are suggested as second‐line therapies for irritable bowel syndrome (IBS). Direct comparative data are limited.

Aims

To compare the efficacy of rifaximin and LFD in IBS.

Methods

In this single‐blind, randomised controlled trial, we allocated adults with IBS to rifaximin or LFD. The primary outcome was composite symptom improvement (abdominal pain/discomfort and stool consistency/frequency) at Week 4. Secondary outcomes included individual symptom improvement, ≥ 50 point reduction in IBS Symptom Severity Scale (IBS‐SSS), health‐related quality of life (HRQOL), Hospital Anxiety and Depression Scale (HADS), small intestinal bacterial overgrowth (SIBO) eradication, adherence and adverse events.

Results

We randomised 100 patients equally (median age 50 years; 52% female; 68% IBS‐D; 17% SIBO). Based on the composite symptom assessment, response rates were similar between groups (rifaximin 56.0% vs. LFD 48.0%, p = 0.423) at Week 4. However, rifaximin led to significantly earlier individual symptom improvement at Week 2, including global symptoms (90.0% vs. 72.0%, p = 0.022), bloating (84.0% vs. 58.0%, p = 0.004) and abdominal pain (80.0% vs. 58.0%, p = 0.017). HRQOL and anxiety scores improved in both groups. SIBO eradication was observed in 63.6% (rifaximin) and 50.0% (LFD). Adherence was significantly better with rifaximin (95.9% vs. 77.8%, p = 0.008). No serious adverse events occurred.

Conclusion

Rifaximin is as effective as LFD in treating IBS over 4 weeks. However, it provides faster symptom relief and higher treatment adherence, making it a practical alternative for symptom management. Trial Registration ClinicalTrials.gov: NCT number: NCT04841980

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diet, Carbohydrate-RestrictedGastrointestinal AgentsIrritable Bowel SyndromeRifamycinsAdultFemaleHumansMaleMiddle AgedFODMAP DietQuality of LifeRifaximinSingle-Blind MethodTreatment Outcome

Stichwörter der Autor:innen

bacterial overgrowthdisorder of gut brain interactionirritable bowel syndromelow FODMAP dietrifaximin

Substanzen

Gastrointestinal AgentsRifamycinsRifaximin

Autor:innen und Institutionen

  • Gastroenterology and Hepatology Unit, Department of Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
  • Staff & Student Health Unit, Universiti Malaya Medical Centre, Kuala Lumpur, Malaysia.
  • Centre for Population Health (CePH), Department of Social and Preventive Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
  • School of Health Rehabilitation Sciences, Health Sciences University, Bournemouth, UK.

ORCID-Profile: Kee Huat Chuah, Sanjiv Mahadeva

Förderung

  • UMSC C.A.R.E Research Grant

Zitieren

APA

Chuah, K. H., Loo, Q. Y., Loh, A. J. C., Leong, J. Y., Chan, W. L., Khoo, X. H., Wong, K. L., Panirsheeluam, S., Natarajan, V., Ng, A. K., Abdul Majid, H., & Mahadeva, S. (2026). Clinical Trial: Rifaximin Versus Low FODMAP Diet in Irritable Bowel Syndrome. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70420

Vancouver

Chuah KH, Loo QY, Loh AJC, Leong JY, Chan WL, Khoo XH, et al. Clinical Trial: Rifaximin Versus Low FODMAP Diet in Irritable Bowel Syndrome. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70420

BibTeX
@article{Chuah2026,
  author = {Chuah, Kee Huat and Loo, Qing Yuan and Loh, Audrey Joe Chii and Leong, Jing Yi and Chan, Wah Loong and Khoo, Xin Hui and Wong, Kim Leng and Panirsheeluam, Sarala and Natarajan, Vicraman and Ng, Ai Kah and Abdul Majid, Hazreen and Mahadeva, Sanjiv},
  title = {Clinical Trial: Rifaximin Versus Low FODMAP Diet in Irritable Bowel Syndrome},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1111/apt.70420}
}
Kostenlos starten →